Skip to main content

Table 2 Univariate analysis for EOR, adjuvant therapy, and WHO classification

From: Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis

 

Overall survival

Progression-free survival

Median

95% CI

Median

95% CI

LD (cm)

 

0.553

 

0.164

 < 5.0

91.52

(65.30, 117.73)

61.31

(40.24, 82.37)

 ≥ 5.0

70.23

(53.28, 87.18)

42.04

(27.29,56.80)

EORa

 

0.270

 

0.024

 GTR

92.68

(72.65, 112.72)

60.66

(44.89, 76.44)

 STR

88.57

(65.59, 111.55)

36.73

(22.60, 50.85)

Adjuvant therapy

 

0.057

 

0.06

 With AT

99.98

(83.45, 116.53)

51.46

(39.09, 63.84)

 Without AT

30.38

(21.14, 39.61)

22.14

(10.33, 33.95)

WHO gradea

 

0.254

 

0.017

 Grade I

92.54

(54.61, 130.48)

86.00

(74.12, 97.88)

 Grade II

–

–

26.09

(18.04, 34.14)

 Grade III

81.81

(69.58, 103.04)

40.46

(28.46, 52.46)

  1. aEOR and WTO grade were statistically significant in PFS